Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL: retreatment with venetoclax and acalabrutinib after prior fixed-duration venetoclax-based therapy in relapsed CLL/SLL
2023-505449-18-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by HOVON. Primary endpoint: uMRD in bone marrow after 26 cycles. Planned start Jul 2020; status: authorised.
02
Drugs
acalabrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-505449-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505449-18-00.